RNAC
Cartesian Therapeutics, Inc.
Key Financials
Operating Income
$-143405000
↓ 226.7%
Revenue
$2.8M
↓ 92.8%
Net Income
$-130302000
↓ 68.3%
Total Assets
$296.4M
↓ 31.9%
EPS (Diluted)
$-5.02
↓ 11.8%
Shareholders' Equity
$-126240000.00
↓ 1755.9%
Total Liabilities
$422.7M
↓ 4.3%
Cash & Equivalents
$125.1M
↓ 41.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/6/2026 | View on SEC |
| 4 | 4/6/2026 | View on SEC |
| SCHEDULE 13D/A | 4/2/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 4 | 3/13/2026 | View on SEC |
| SCHEDULE 13G | 3/13/2026 | View on SEC |
| 10-K | 3/9/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| SCHEDULE 13G/A | 2/5/2026 | View on SEC |
| 144 | 1/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNAC |
| Company Name | Cartesian Therapeutics, Inc. |
| CIK | 1453687 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 301-348-8698 |